Medication Description: Ondansetron (Ondansetron)
4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3 - [(2-methyl-1H-imidazol-1-yl) methyl].
Available as monohydrochloride.
Synonyms: Zofran, Latran, Ondazan, Osetron, Emeset, Emetron, Emeset, Latran, Ondansetron, Ondasan, Osetron, Zofran.
White or almost crystalline powder. Soluble in water.
It has an antiemetic effect, which is associated with the blocking of peripheral and central serotonin (5-HT3) receptors (see Serotonin).
When ingested, it is well absorbed, bioavailability is about 56%, Cmax - with intravenous and oral administration - 10 minutes and 1.7 hours, respectively, T1 / 2 - 3.0-5.5 hours; undergoes biotransformation in the liver, excreted by the kidneys mainly in the form of metabolites.
Applied with vomiting associated with chemotherapy or radiation therapy of malignant tumors in the postoperative period. Warns or eliminates vomiting.
Assign intravenously, intramuscularly, inside and rectally.
With moderate emetogenic chemotherapy and radiation therapy, 0.008 g (8 mg) is administered intravenously before the course, or orally for Ѕ-2 h before the course and 8-12 h after the course, or 0.016 g (16 mg) rectally for 1- 2 hours before the course, or infusion of 0.032 g (32 mg) for 15 minutes 30 minutes before the course, or 0.15 mg / kg 3 times - 30 minutes before and then 4 and 8 hours after the course.
For the prevention of late nausea and vomiting, 0.008 g is administered orally, 2 times a day or rectally, 0.016 g (16 mg) once a day for 1-2 days (up to 3-5 days) after completing the course of chemotherapy.
Doses of the drug are selected individually depending on the effect and tolerability.
Children are injected into the vein at the rate of 5 mg / m2 of body surface; for the prevention of vomiting prescribed in tablets of 0.004 g (4 mg), 2 times a day.
The use of the drug may cause headache, diarrhea or constipation, dry mouth, hiccups, liver failure, accommodation disturbances, paresthesias, extrapyramidal disorders, hypotension, arrhythmias, bronchospasm, allergic skin reactions.
Contraindications: liver failure; I trimester of pregnancy, breastfeeding.
Method of production: tablets of 0.004 and 0.008 g (4 and 8 mg) (N. 10); rectal suppositories of 0.004; 0.008 and 0.016 g (4, 8, and 16 mg); 0.08% syrup in bottles of 50 ml; 0.2% solution in ampoules of 2 and 4 ml.
Storage: List B.